| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/2047487312448994 |
| P698 | PubMed publication ID | 22988567 |
| P50 | author | Maarten J. Postma | Q87840199 |
| P2093 | author name string | Petros Pechlivanoglou | |
| Jelena Stevanovic | |||
| P2860 | cites work | Executive Summary: Heart Disease and Stroke Statistics--2012 Update: A Report From the American Heart Association | Q22241920 |
| Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study | Q24630111 | ||
| Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis | Q28218996 | ||
| Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study | Q28257557 | ||
| General cardiovascular risk profile for use in primary care: the Framingham Heart Study | Q29614189 | ||
| Final report on the aspirin component of the ongoing Physicians' Health Study | Q29619461 | ||
| Changes in estimated coronary risk in the 1980s: data from 38 populations in the WHO MONICA Project. World Health Organization. Monitoring trends and determinants in cardiovascular diseases | Q32053074 | ||
| Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines | Q34347054 | ||
| Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database | Q34394948 | ||
| Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project | Q34534248 | ||
| Cost-utility of aspirin and proton pump inhibitors for primary prevention | Q35108108 | ||
| Selecting methods for the prediction of future events in cost-effectiveness models: a decision-framework and example from the cardiovascular field | Q35126849 | ||
| The applicability of the Framingham coronary heart disease prediction function to black and minority ethnic groups in the UK | Q35581340 | ||
| Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review | Q35772791 | ||
| Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC) | Q35773156 | ||
| Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. | Q35902547 | ||
| The role of global risk assessment in hypertension therapy | Q36498050 | ||
| Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. | Q36738148 | ||
| European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice ... | Q36921887 | ||
| Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective? | Q37098508 | ||
| Predicting the 30-year risk of cardiovascular disease: the framingham heart study | Q37356527 | ||
| C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. | Q37363683 | ||
| 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations | Q37435149 | ||
| Cardiovascular risk-estimation systems in primary prevention: do they differ? Do they make a difference? Can we see the future? | Q37774162 | ||
| Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study | Q40664994 | ||
| At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? | Q40699993 | ||
| Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention | Q40865204 | ||
| Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation | Q43742848 | ||
| The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis | Q43900462 | ||
| Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece | Q44573481 | ||
| Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering | Q46111114 | ||
| Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany | Q47316170 | ||
| Economic burden of cardiovascular diseases in the enlarged European Union | Q50116064 | ||
| Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. | Q51166228 | ||
| Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. | Q51922378 | ||
| Framingham risk function overestimates risk of coronary heart disease in men and women from Germany—results from the MONICA Augsburg and the PROCAM cohorts | Q52017724 | ||
| Cardiovascular disease risk profiles. | Q52461317 | ||
| An updated coronary risk profile. A statement for health professionals. | Q52461335 | ||
| A comparison of Framingham and SCORE-based cardiovascular risk estimates in participants of the German National Health Interview and Examination Survey 1998. | Q52936363 | ||
| Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age | Q57413995 | ||
| Probability of stroke: a risk profile from the Framingham Study | Q57746223 | ||
| P433 | issue | 2 Suppl | |
| P921 | main subject | systematic review | Q1504425 |
| P304 | page(s) | 42-53 | |
| P577 | publication date | 2012-08-01 | |
| P1433 | published in | European Journal of Preventive Cardiology | Q2493290 |
| P1476 | title | A systematic review on the application of cardiovascular risk prediction models in pharmacoeconomics, with a focus on primary prevention | |
| P478 | volume | 19 |
Search more.